ECSP088619A - Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva - Google Patents

Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva

Info

Publication number
ECSP088619A
ECSP088619A EC2008008619A ECSP088619A ECSP088619A EC SP088619 A ECSP088619 A EC SP088619A EC 2008008619 A EC2008008619 A EC 2008008619A EC SP088619 A ECSP088619 A EC SP088619A EC SP088619 A ECSP088619 A EC SP088619A
Authority
EC
Ecuador
Prior art keywords
treatment
combination
antagonist
inhibitor
acetilcolinesterase
Prior art date
Application number
EC2008008619A
Other languages
English (en)
Inventor
Lee Erwin Schechter
Thomas Anthony Comery
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088619A publication Critical patent/ECSP088619A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención suministra un método para el tratamiento de un trastorno cognitivo tal como la enfermedad de Alzheimer en un paciente que lo necesita que comprende suministrar a dicho paciente una cantidad terapéuticamente efectiva de una combinación de un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6.
EC2008008619A 2006-01-13 2008-07-11 Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva ECSP088619A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75884106P 2006-01-13 2006-01-13

Publications (1)

Publication Number Publication Date
ECSP088619A true ECSP088619A (es) 2008-08-29

Family

ID=38109582

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008619A ECSP088619A (es) 2006-01-13 2008-07-11 Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva

Country Status (20)

Country Link
US (1) US20070167431A1 (es)
EP (1) EP1971334A2 (es)
JP (1) JP2009523728A (es)
KR (1) KR20080096657A (es)
CN (1) CN101370499A (es)
AR (1) AR060019A1 (es)
AU (1) AU2007208516A1 (es)
BR (1) BRPI0706515A2 (es)
CA (1) CA2635920A1 (es)
CR (1) CR10139A (es)
EC (1) ECSP088619A (es)
GT (1) GT200800138A (es)
IL (1) IL192694A0 (es)
MX (1) MX2008009021A (es)
NO (1) NO20082894L (es)
PE (1) PE20071143A1 (es)
RU (1) RU2008126245A (es)
TW (1) TW200733976A (es)
WO (1) WO2007087151A2 (es)
ZA (1) ZA200806070B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
US20100120747A1 (en) * 2006-06-23 2010-05-13 Laboratorios Del Dr. Esteve, S.A. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
AR061637A1 (es) * 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
RU2467749C1 (ru) * 2011-04-21 2012-11-27 Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ коррекции уровня сахара крови и лечения пациентов с сахарным диабетом второго типа с когнитивными нарушениями
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
WO2016071293A2 (en) 2014-11-03 2016-05-12 Iomet Pharma Ltd Pharmaceutical compound
WO2016179569A1 (en) * 2015-05-07 2016-11-10 Axovant Sciences Ltd. Compositions and methods of treating a neurodegenerative disease
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
RU2018103338A (ru) 2015-07-15 2019-08-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием
WO2017147601A1 (en) * 2016-02-25 2017-08-31 Axovant Sciences Gmbh Methods of improving balance, gait or both in patients with neurological disease
DK3448430T3 (da) * 2016-04-26 2023-07-03 H Lundbeck As Anvendelse af en acetylcholinesterase-inhibitor og idalopirdin til reduktion af fald hos patienter med parkinsons sygdom
US10864191B2 (en) * 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
RS60422B1 (sr) * 2016-05-18 2020-07-31 Suven Life Sciences Ltd Kombinacija čistih antagonista 5-ht6 receptora sa inhibitorima acetilholinesteraze

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006205B1 (ru) * 2000-11-02 2005-10-27 Уайт 1-арил- или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
EP1572205A2 (en) * 2002-12-11 2005-09-14 Pharmacia & Upjohn Company LLC Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
WO2004074243A2 (en) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
RU2429231C2 (ru) * 2005-08-15 2011-09-20 Вайет Производные замещенного-3-сульфонилиндазола в качестве лигандов 5-гидрокситриптамина-6

Also Published As

Publication number Publication date
PE20071143A1 (es) 2008-01-20
KR20080096657A (ko) 2008-10-31
GT200800138A (es) 2008-10-06
BRPI0706515A2 (pt) 2011-03-29
CN101370499A (zh) 2009-02-18
NO20082894L (no) 2008-09-30
TW200733976A (en) 2007-09-16
CR10139A (es) 2008-09-30
AU2007208516A1 (en) 2007-08-02
AU2007208516A8 (en) 2008-08-07
RU2008126245A (ru) 2010-02-20
CA2635920A1 (en) 2007-08-02
IL192694A0 (en) 2009-02-11
US20070167431A1 (en) 2007-07-19
AR060019A1 (es) 2008-05-21
WO2007087151A2 (en) 2007-08-02
MX2008009021A (es) 2008-09-24
JP2009523728A (ja) 2009-06-25
EP1971334A2 (en) 2008-09-24
ZA200806070B (en) 2009-04-29
WO2007087151A3 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
ECSP088619A (es) Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CL2008001374A1 (es) Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
ME01532B (me) Jedinjenja
GT200500098A (es) Nuevos compuestos
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
BRPI1006115A2 (pt) "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
EA201100544A1 (ru) Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли
CL2011000043A1 (es) Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
ATE510538T1 (de) Zusammensetzungen und verfahren für nervenschutz
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
CR10730A (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
CR10336A (es) Compuestos organicos y sus usos
UY29995A1 (es) Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY30986A1 (es) Derivados fluorinados de deferiprona
RS51069B (sr) Upotreba oksikodona za tretiranje visceralnog bola
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
MX2010001449A (es) Bromhidrato de bupropion y aplicaciones terapeuticas.
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas